How It Works

A simple laparoscopic surgery means no new skills needed for medical professionals and quick and easy relief for patients with acid reflux.

OmegaCuff’s main differentiator from other competitors on the market is that it is a partial surround device (partial fundoplication) with a mechanical advantage for swallowing. Less problems arise post-op due to the device’s intuitive design, allowing it to not disrupt physiology or anatomy. Plus, the surgury takes less than an hour, and does not require any new training or skills from the medical staff.

Several key opinion leaders in the field of gastroenterology and GI surgery have provided valuable input and advice on this project including Robert A. Ganz, MD, an ASGE Schindler awardee. We look forward to continuing our working relationship with Dr Ganz on the medical advisory board, and others, as the product moves to the clinical testing stages.

Some other key factors:

  • OmegaCuff is a nitinol device that is easy to manufacture.
  • OmegaCuff’s design avoids dysphagia.
  • The simple surgery means no nerve manipulation.
  • OmegaCuff’s large, flat footprint minimizes erosion.
  • OmegaCuff does not prevent patients from receiving MRI diagnostic procedures.
  • OmegaCuff did not have any adverse events in its GLP animal study.
  • OmegaCuff has passed all FDA required pre-clinical safety and efficacy study requirements, and has been granted an IDE to begin clinical studies.

A Widespread health issue

Over 300 Million people worldwide experience symptoms of acid reflux.

GERD (gastroesophageal reflux disease), or acid reflux, affects conservatively over 7% of adults worldwide, with with 60-80 million people affected in the U.S. alone. Medication such as proton pump inhibitors (PPIs) reduce the effect of the reflux but not the reflux condition itself, and can cause serious side effects with long-term use.

OmegaCuff™ is and ideal option for patients who have failed at instituting lifestyle modifications and PPI management.

Start A Conversation

We are currently seeking investors to help our mission to improve the quality of lives for millions of patients with with next generation therapies.

Are you looking for a significant business opportunity? OmegaCuff is a greatly derisked next generation device that is patented in U.S., China and Europe. We are looking for funding to support our FDA approved clinical studies.

Interested in working with Aplos Medical or learning more about our products and services? You can contact us via the information below, or fill the form provided.

Claude Tihon, PhD. | President & CEO
Phone: (952) 944–3749
Email: claude@aplosmed.com